Related Experiment Video
Updated: May 4, 2026

Measuring Microbial Mutation Rates with the Fluctuation Assay
Published on: November 28, 2019
Mutagenic assessment of olmesartan cilexetil by bacterial mutation assay
Ji Won Kim1, Ilyoung Ahn2, Sung Ha Ryu3
1Department of Pharmacology, CKD Research Institute, Yongin, Korea.
Abstract:
Hypertension is a serious health problem due to high frequency and concomitant other diseases including cardiovascular and renal dysfunction. Olmesartan cilexetil is a new antihypertensive drug associated with angiotensin II receptor antagonist. This study was conducted to evaluate the mutagenicity of olmesartan cilexetil by bacterial reverse mutation test using Salmonella typhimurium (TA100, TA1535, TA98, and TA1537) and Escherichia coli (WP2 uvrA). At the concentrations of 0, 62, 185, 556, 1667, and 5000 μg/ plate, olmesartan cilexetil was negative in both Salmonella typhimurium and Escherichia coli regardless of presence or absence of metabolic activation system (S9 mix). These results demonstrate that olmesartan cilexetil does not induce bacterial reverse mutation.
Insights
Olmesartan cilexetil, an antihypertensive drug, was evaluated for mutagenicity. The drug demonstrated no mutagenic potential in bacterial reverse mutation tests using Salmonella typhimurium and Escherichia coli.
Area of Science:
- Pharmacology
- Toxicology
- Genetics
Background:
- Hypertension is a prevalent health issue linked to cardiovascular and renal complications.
- Olmesartan cilexetil is an angiotensin II receptor antagonist used for hypertension treatment.
Purpose of the Study:
- To assess the mutagenicity of olmesartan cilexetil.
- Evaluate potential DNA damage induced by the drug.
Main Methods:
- Bacterial reverse mutation assay (Ames test).
- Utilized Salmonella typhimurium strains (TA100, TA1535, TA98, TA1537) and Escherichia coli (WP2 uvrA).
- Tested olmesartan cilexetil at concentrations ranging from 0 to 5000 μg/plate, with and without metabolic activation (S9 mix).
Main Results:
- Olmesartan cilexetil tested negative for mutagenicity in all bacterial strains.
- No reverse mutations were observed in Salmonella typhimurium or Escherichia coli.
- Results were consistent with and without the presence of a metabolic activation system.
Conclusions:
- Olmesartan cilexetil does not induce bacterial reverse mutations.
- The drug is non-mutagenic in the bacterial reverse mutation test.
- Supports the safety profile of olmesartan cilexetil regarding genotoxicity.
Related Concept Videos
Mutagenicity and Carcinogenicity
In vitro Mutagenesis
In-vitro Mutagenesis
Mutations in Microorganisms
Mismatch Repair
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...

